SOURCE: OmniComm Systems, Inc.
FORT LAUDERDALE, FL--(Marketwire - Apr 25, 2012) - OmniComm Systems, Inc. (OTCBB: OMCM), one of the fastest growing companies in the EDC marketplace today, announced that its TrialMaster® suite of applications and Interactive Web Response (IWR) solution has been chosen by this US-based biotechnology company to manage the clinical data management needs for this 2 year, 700+ subject, multi-national trial with over 60 sites across 6 countries.
"This large complex clinical trial is actually a follow-on study," said Stephen Johnson, President & COO of OmniComm. "We are very pleased that this biotech company has once again trusted us for such an important study. It speaks volumes to the level of support that we've provided thus far."
OmniComm will be designing and hosting this study and randomization of patients will be done through its web-based IWR solution. The study design will deploy CDISC standards for CDASH and SDTM to facilitate rapid data collection, processing and exporting of study data. OmniComm's world-class help desk, offering support in 14 different languages, will also be instrumental in ensuring a successful trial.
OmniComm Systems, Inc. (www.OmniComm.com) provides customer-driven Internet solutions to pharmaceutical, biotechnology, research and medical device organizations that conduct life changing clinical trial research. OmniComm's growing base of satisfied customers is a direct result of the company's commitment to deliver products and services that ensure ease of use, faster study build, ease of integration and better performance. OmniComm's pricing model is easily understood and allows companies ranging from small, to large, to maximize their clinical research investments. OmniComm Systems, Inc. has U.S. headquarters in Fort Lauderdale, FL and European headquarters in Bonn, Germany, with satellite offices in New Jersey and the United Kingdom, as well as sales offices throughout the U.S. and Europe.
Safe Harbor Disclaimer
Statements made by OmniComm included in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as the Company's ability to obtain new contracts and accurately estimate net revenues due to uncertain regulatory guidance, variability in size, scope and duration of projects, and internal issues at the sponsoring client, integration of acquisitions, competitive factors, technological development, and market demand. As a result, actual results may differ materially from any financial outlooks stated herein. Further information on potential factors that could affect the Company's financial results can be found in the Company's Reports on Form 10-K and 10-Q filed with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.